SCHEMBL2371199

SCHEMBL2371199

COc1ccc(Oc2cc(F)c(Br)cc2C(=O)O)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
POLB P06746 1/20 0.51
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
SCN8A Q9UQD0 2/20 0.42
SCN10A Q9Y5Y9 2/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
ALDH1A1 P00352 2/20 0.42
CPS1 P31327 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
PRKAB2 O43741 1/20 0.40
PRKAG1 P54619 1/20 0.40
PRKAA2 P54646 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PRKAG3 Q9UGI9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369905 0.85 KDM4E (0.56) KDM4EPOLBLMNAHTTMAPK1
SCHEMBL2372284 0.82 POLB (0.68) KDM4EPOLBLMNAHTTMAPK1
SCHEMBL2371797 0.80 KDM4E (0.44) KDM4EPOLBLMNAHTTMAPK1
SCHEMBL4600091 0.79 LCK (0.59) KDM4ELMNAHTTMAPK1RAB9A
SCHEMBL30316008 0.79 LCK (0.59) KDM4ELMNAHTTMAPK1RAB9A
Hydrochloric Acid SCHEMBL10978550 0.78 LCK (0.58) KDM4ELMNAHTTMAPK1RAB9A
SCHEMBL2371102 0.75 LCK (0.47) KDM4EPOLBLMNAHTTMAPK1
SCHEMBL1051747 0.74 CPS1 (0.63) KDM4ELMNARAB9AALDH1A1CPS1
SCHEMBL19667102 0.73 LCK (0.65) KDM4ELMNAHTTMAPK1RAB9A
SCHEMBL503802 0.72 POLB (0.70) KDM4EPOLBLMNAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP KDM4E 2994/4885POLB 3640/4885LMNA 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.